Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypidone Hydrochloride Multiple-Dose Tolerability and PK Study
NCT04598607Phase 1Completed
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hypidone in major depressive disorder (MDD) (6 arms), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started Oct 2020; status: completed.
02
Drugs
hypidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04598607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598607.